GlassScriptPhysician profile
Parvin Salari
NPI 1740650712
$3,809.86
in general payments reported to CMS, 2019-2025
24 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $429 · 2023: $660 · 2024: $492 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,712.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $856.22 | 2021-2025 | |
| Amgen INC. | $655.73 | 2021-2025 | Otezla, Enbrel, Evenity |
| Janssen Biotech, INC. | $392.46 | 2021-2025 | Tremfya |
| Pfizer INC. | $387.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $381.06 | 2022-2025 | |
| Glaxosmithkline, LLC. | $301.14 | 2021-2025 | Benlysta |
| Ucb, INC. | $216.75 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $107.17 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $90.50 | 2023-2025 | Saphnelo, Tezspire |
| Mallinckrodt Hospital Products INC. | $66.95 | 2021-2022 | |
| Organon LLC | $60.58 | 2021-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $44.88 | 2021-2024 | Strensiq |
| Bioventus LLC | $37.71 | 2025 | Durolane |
| Mylan Institutional INC. | $23.93 | 2023 | Hulio |
| Ani Pharmaceuticals, INC. | $23.69 | 2025 | Sovuna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.33 | 2022 | |
| Biocon Biologics INC | $19.99 | 2023 | Hulio |
| Radius Health, INC. | $19.71 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $19.68 | 2023 | Opsumit, Uptravi |
| Genentech USA, INC. | $19.07 | 2023 | Lunsumio, Polivy |
| Sandoz INC. | $18.59 | 2023 | Hyrimoz |
| Horizon Therapeutics Plc | $17.71 | 2023 | Krystexxa |
| Invivyd INC | $14.42 | 2024 | Pemgarda |
| Arteriocyte Medical Systems, INC. | $13.89 | 2023 | Magellan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvin Salari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.